BACKGROUND: Despite the efficacy of raltegravir in reducing viral load in HIV-infected patients, evidence for its safety in late pregnancy is lacking. A high rate of placental transfer was recently demonstrated. CASE: A treatment-naïve 34-year-old HIV-1-positive woman of African origin began treatment with zidovudine/lamivudine, lopinavir/ritonavir, and raltegravir at 35 weeks of pregnancy. After 11 days of treatment with raltegravir, a substantial reduction in viral load was achieved. Concurrently, she had a 23-fold increase in serum alanine aminotransferase and a 10-fold increase in serum aspartate aminotransferase, both of which returned to normal when raltegravir treatment was discontinued. A healthy boy was delivered at term. The infant's tests for HIV were negative at five months, and he had no health problems at eight months. CONCLUSION: This is the first case report, to our knowledge, of increased maternal serum transaminase levels following the use of raltegravir in a woman at a late stage of pregnancy.
BACKGROUND: Despite the efficacy of raltegravir in reducing viral load in HIV-infectedpatients, evidence for its safety in late pregnancy is lacking. A high rate of placental transfer was recently demonstrated. CASE: A treatment-naïve 34-year-old HIV-1-positive woman of African origin began treatment with zidovudine/lamivudine, lopinavir/ritonavir, and raltegravir at 35 weeks of pregnancy. After 11 days of treatment with raltegravir, a substantial reduction in viral load was achieved. Concurrently, she had a 23-fold increase in serum alanine aminotransferase and a 10-fold increase in serum aspartate aminotransferase, both of which returned to normal when raltegravir treatment was discontinued. A healthy boy was delivered at term. The infant's tests for HIV were negative at five months, and he had no health problems at eight months. CONCLUSION: This is the first case report, to our knowledge, of increased maternal serum transaminase levels following the use of raltegravir in a woman at a late stage of pregnancy.
Authors: Lisa Rahangdale; Jordan Cates; JoNell Potter; Martina L Badell; Dominika Seidman; Emilly S Miller; Jenell S Coleman; Gweneth B Lazenby; Judy Levison; William R Short; Sigal Yawetz; Andrea Ciaranello; Elizabeth Livingston; Lunthita Duthely; Bassam H Rimawi; Jean R Anderson; Elizabeth M Stringer Journal: Am J Obstet Gynecol Date: 2016-03 Impact factor: 8.661
Authors: D Heather Watts; Alice Stek; Brookie M Best; Jiajia Wang; Edmund V Capparelli; Tim R Cressey; Francesca Aweeka; Patty Lizak; Regis Kreitchmann; Sandra K Burchett; David E Shapiro; Elizabeth Hawkins; Elizabeth Smith; Mark Mirochnick Journal: J Acquir Immune Defic Syndr Date: 2014-12-01 Impact factor: 3.731
Authors: I Boucoiran; K Tulloch; N Pick; F Kakkar; J van Schalkwyk; D Money; M Boucher Journal: Can J Infect Dis Med Microbiol Date: 2015 May-Jun Impact factor: 2.471